GENF vs. OBI, SAR, POLB, OKYO, AREC, AOR, OPTI, IMM, RLM, and NSCI
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include Ondine Biomedical (OBI), Sareum (SAR), Poolbeg Pharma (POLB), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), AorTech International (AOR), OptiBiotix Health (OPTI), ImmuPharma (IMM), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.
Genflow Biosciences vs.
Ondine Biomedical (LON:OBI) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Ondine Biomedical has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.
Ondine Biomedical received 1 more outperform votes than Genflow Biosciences when rated by MarketBeat users.
Genflow Biosciences has lower revenue, but higher earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.
Ondine Biomedical has a net margin of 0.00% compared to Genflow Biosciences' net margin of -256.07%. Genflow Biosciences' return on equity of -118.88% beat Ondine Biomedical's return on equity.
In the previous week, Ondine Biomedical's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.
20.6% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 9.2% of Genflow Biosciences shares are owned by institutional investors. 36.7% of Ondine Biomedical shares are owned by insiders. Comparatively, 64.2% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Genflow Biosciences beats Ondine Biomedical on 7 of the 11 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
This page (LON:GENF) was last updated on 1/22/2025 by MarketBeat.com Staff
Free GENF Stock Alerts